KLRC1
ENSG00000134545
Target class
Unclassified protein
Chromosome
12
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- KLRC1
- Gene name
- Killer cell lectin like receptor C1
- Gene symbol
- KLRC1
- Previous gene symbols
- NKG2
- Protein name
- NKG2-A/NKG2-B type II integral membrane protein (CD159 antigen-like family member A) (NK cell receptor A) (NKG2-A/B-activating NK receptor) (CD antigen CD159a)
- NKG2-A
- NKG2-B
- CD159a
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Killer cell lectin like receptors|C-type lectin domain containing
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 4
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 3.79
- Tissue specificity (Gini)
- 0.599
- Tissue specificity (tau)
- 0.919
- KEGG gene identifiers
- hsa:3821
- Reactome pathways
- R-HSA-198933
- Protein interaction confidence
- 0.86034
- Protein interaction partners
- 50
- End position
- 10454685
- Start position
- 10442264
- Chromosome
- 12
- Strand
- Reverse
- Cell membrane
- Single-pass type II membrane protein .
- Plasma membrane
- PubMed 12165520
- PubMed 20952657
- Tissue specificity (tau)
- 0.919351
- Expression inequality (Gini)
- 0.59892
Expression in transcripts per million
- Spleen
- 3.79
- Lung
- 1.54
- Small Intestine - Terminal Ileum
- 1.08
- Whole Blood
- 1.05
- Stomach
- 0.9
Expression in transcripts per million
- Spleen3.79
- Lung1.54
- Small Intestine - Terminal Ileum1.08
- Whole Blood1.05
- Stomach0.9
- Fallopian Tube0.87
- Testis0.8
- Thyroid0.71
- Prostate0.62
- Bladder0.59
- Artery - Aorta0.55
- Minor Salivary Gland0.55
- Colon - Transverse0.52
- Adipose - Visceral (Omentum)0.51
- Vagina0.49
- Cervix - Endocervix0.44
- Brain - Spinal cord (cervical c-1)0.41
- Artery - Coronary0.36
- Esophagus - Mucosa0.29
- Breast - Mammary Tissue0.27
- Esophagus - Muscularis0.25
- Uterus0.24
- Pituitary0.24
- Adipose - Subcutaneous0.22
- Liver0.21
And 29 more, listed on the interactive page.
- GO:0001915
- GO:0002305
- GO:0002769
- GO:0007166
- GO:0045953
- GO:0005886
- GO:0043235
- GO:0004888
- GO:0005515
- GO:0023024
- GO:0062080
- GO:0062082
- GO:1990405
Related records
Trials (24)
- A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
- A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
- A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
- A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
- Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
- Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
- Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA
- Biomarker-based Study in R/M SCCHN
- Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL
- Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
- Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity
- Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer
- Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial
- MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
- Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
- Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance
- Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection
- Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation
Drugs (1)
- Monalizumab NKG2-A/NKG2-B type II integral membrane protein inhibitor